A phase 2, open-label study of nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) in patients with recurrent high grade glioma following prior therapy and subjects with newly diagnosed glioblastoma. ABI-009 will be tested as single agent or in combination with standard therapies.
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and subjects with newly diagnosed glioblastoma. nab-sirolimus will be tested as single agent or in combination with standard therapies.